Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG2210 TRANSFER: Autologous stem cell transplantation vs observation in peripheral T-cell lymphoma with complete metabolic response
jRCTs031240169Phase 3Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of brentuximab vedotin, cyclophosphamide, doxorubicin, vincristine, prednisolone and 7 more in peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma (FTCL) and 2 more (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival. Started Aug 2024; status: recruiting.
02
Drugs
brentuximab vedotincyclophosphamidedoxorubicinvincristineprednisolone
03
Conditions
peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)angioimmunoblastic T-cell lymphoma (AITL)follicular T-cell lymphoma (FTCL)T-cell lymphoma follicular helper (TFHL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on jRCTs031240169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240169.